ESC Professional Premium Access

Efficacy of ertugliflozin on hospitalisation for heart failure across the distribution of pre-trial ejection fraction: post hoc analyses of the VERTIS CV trial

Congress Session

About the speaker

Doctor Ambarish Pandey

University of Texas Southwestern Medical Center, Dallas (United States of America)
0 follower

3 more presentations in this session

The real-world safety profile of SGLT2 inhibitors among adults 75 years or older: a retrospective, pharmacovigilance study

Speaker: Assistant Professor E. Maor (Tel Aviv, IL)

Thumbnail

Outcomes related to IGFBP-7 in patients with heart failure and reduced ejection fraction and effects of dapagliflozin: findings from DAPA-HF

Speaker: Doctor C. Adamson (Glasgow, GB)

Thumbnail

Relationship between endothelin-1, heart failure with reduced ejection fraction and dapagliflozin: findings from DAPA-HF

Speaker: Doctor K. Docherty (Glasgow, GB)

Thumbnail

Access the full session

SGLT2 inhibitors: pearls from recent trials and surveys

Speakers: Doctor A. Pandey, Assistant Professor E. Maor, Doctor C. Adamson, Doctor K. Docherty
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

This platform is supported by

logo Novo Nordisk